Bronchodilator treatment for asthma and COPD

Thematic Poster Session
Chairs: P. Kirkham (London, United Kingdom), G. Caramori (Ferrara, Italy)

Local and system effects of tiotropium bromide (TB) T. Pertseva, O. Lykholat, O. Gurzhiy (Dnepropetrovsk, Ukraine)
Absolute bioavailability of inhaled aclidinium bromide and safety and tolerability of aclidinium bromide administered intravenously in healthy subjects S. Ortiz, S. Flach, C. Caracta, E. Garcia Gil, J. Jansat (Jersey City, Madison, United States Of America; Barcelona, Spain)
The combination therapy with inhaled tiotropium bromide and transdermal tulobuterol in COPD improves the peripheral airway function T. Abe, Y. Setoguchi (Shinjyuku-ku, Japan)
LAS100977 is a novel, potent β₂-agonist with rapid onset and sustained duration of action in vitro M. Aparici, M. Gómez-Angelats, D. Vilella, J. Cortijo, E. Morcillo, C. Carcasona, A. Gavaldà, J. Beleta, C. Puig, H. Ryder, M. Miralpeix (Barcelona, València, Spain)
Aclidinium bromide improves resting lung function in patients with moderate to severe COPD B. Celli, F. Maltais, R. Casaburi, J. Porszasz, E. Garcia Gil, C. Caracta (Boston, Torrance, Jersey City, United States Of America; Québec, Canada; Barcelona, Spain)
The therapeutic index of vilanterol trifenatate (VI) A. Ford, S. Hughes, C. Smith, G. Somers, L. Ranshaw (Stevenage, United Kingdom)
Safety of vilanterol trifenatate (VI) in a COPD dose-ranging study N. Hanania, G. Feldman, W. Zachgo, J. J. Shim, C. Crim, L. Sanford, S. Lettis, F. Barnhart, B. Haumann (Houston, Spartanburg, RTP, United States Of America; Geesthacht, Germany; Seoul, Republic Of Korea; London, United Kingdom)
Efficacy of tiotropium in COPD patients with FEV₁ ≥ 60% participating in the UPLIFT trial D. Tashkin, B. Celli, T. Lystig, S. Kesten, M. Decramer (Los Angeles, Boston, Ridgefield, United States Of America; , Belgium)
In vivo, aclidinium bromide has longer duration of action and reduced potential to induce dry mouth, compared with glycopyrrolate R. Otal, A. Gavalda, J. Llupià, J. Beleta, M. Miralpeix (Barcelona, Spain)
LAS100977, a novel, selective, long-acting β₂-agonist, improves airway conductance and reduces airway resistance in healthy subjects W. Timmer, E. Massana, E. Jiménez, B. Seoane, G. de Miquel, S. Ruiz (Mannheim, Germany; Barcelona, Spain)
Premature discontinuation during the UPLIFT study M. Decramer, G. Molenberghs, B. Celli, S. Kesten, D. Liu, D. Tashkin (Leuven, Belgium; Boston, Ridgefield, Los Angeles, United States Of America)
Indacaterol provides effective bronchodilation in patients with COPD irrespective of age R. Buhl, D. A. Mahler, R. Owen, C. Lassen, B. Kramer (Germany; NH, East Hanover, United States Of America; West Sussex, United Kingdom)
Risk of non-lower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT trial D. Halpin, B. Celli, M. Decramer, S. Kesten, D. Liu, D. Tashkin (Exeter, United Kingdom; Boston, Ridgefield, Los Angeles, United States Of America; Leuven, Belgium)
Pre-exercise inhalation of short-acting ß-agonists (SABA) safely improves exercise performance in severe COPD patients by reducing lung hyperinflation R. Tanaka, M. Miura, Y. Tashiro, S. Yamagata, M. Nihei, T. Hosaka (Sendai, Japan)
Single dose of of tiotropium bromide (18 mcg) produces a similar bronchodilator response as two doses of formoterol fumarate (12 mcg ) over 24 hours in subjects with moderate-to-severe asthma S. Limaye, R. Kodgule, S. Raskar, A. Shaikh, V. vincent, K. Gaikwad, S. Salvi (Pune, India)
Pharmacokinetics and safety of aclidinium bromide in young and elderly patients with COPD S. de la Motte, J. Beier, K. Schmid, J. Ho, S. Pascual, J. Maria Jansat, E. Garcia Gil (Munich, Wiesbaden, Germany; New Jersey, United States Of America; Barcelona, Spain)
A respiratory perspective on long term beta-blocker treatment in patients presenting with acute cardiac disease B. Cochrane, S. Quinn, H. Walters, I. Young (Hobart, Sydney, Australia)
Indacaterol once-daily provides significant bronchodilation irrespective of baseline reversibility in COPD patients E. Kleerup, A. D‘Urzo, R. Owen, C. Lassen, B. Kramer (Los Angeles, East Hanover, United States Of America; Toronto, Canada; West Sussex, United Kingdom)
Airway responsiveness to hyperventilation and vitamin D deficiency C. Bucca, B. Culla, C. Roasio, S. Mietta, A. Moretto, F. De Renzis, L. Brussino, G. Guida (Turin, Italy)
Bronchodilator treatment for asthma and COPD